Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis

• Status: Completed
• Trial end date: 2018-03-27
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.

Criteria

Inclusion Criteria:

1. Liver cirrhosis investigators with age 20 to 80 years (both inclusive).

2. Investigators without Mandatory Communicable Disease (HBV, HCV, HIV, syphilis)

3. Investigators without rare disorder

4. Coagulation normalities

5. Investigators without autoimmune disorder

6. Investigators without Acquired Immune Deficiency Syndrome

7. Investigators without cancer

8. Investigators BMI > 15

Exclusion Criteria:

1. Pregnant women

2. Investigators with acute stroke in one month and unconsciousness

3. Investigators with acute myocardial infarction or acute heart failure

4. Investigators with serious liver dysfunction and coagulation dysfunction and ascites mild higher

5. Investigators with acute respiratory failure or pneumonia

6. Kidney Failure: BUN > 50

7. Anemia: Hematocrit < 25

8. Investigators diagnosed with liver cancer or liver metastatic carcinoma

9. Investigators with liver abscess

10. Investigators with acute Hepatitis

11. Investigators with acute infective

12. Liver cirrhosis patients with HBV or HCV

13. Investigators diagnosed with carcinoma and receiving treatment

14. Investigators with Schizophrenia or melancholia

15. Investigators received serious surgical operations in 3 months

16. Investigators unable to control hypertension (SBP > 180 mmHg, DBP > 110 mmHg) or diabetes (AC sugar > 200 mg/dl)

17. Others can't fit into the trial evaluate by investigator